Immune cell therapy

    Immune cell therapy is an emerging cancer treatment strategy that uses body’s own immune system to fight cancer.  Numerous studies have demonstrated that immune cell therapy can effectively remove small lesions and residual tumor cells, enhance immune function, increase tumor sensitivity to radiotherapy and chemotherapy, and thus improve patients’ survival and overall wellbeing.  Immune cell therapy collect immune cells, such as T cells and natural killer cells, from a patient, culture them under special media with or without genetic modification, expand the immune cells thousands of times, and then infuse the immune cells back to the patient. Those ex vivo expanded immune cells are highly effective to attack and kill pathogens, cancer cells, mutated and damaged cells , etc. Since immune cell therapy possesses double function of treatment and care, it has been recognized as one of the most promising cáncer treatment strategy in the twenty-first century and is currently the world's only hope to eradicate and cure cancer.

 

    In collaboration with experts in cancer immunotherapy field, CIB scientists have developed and optimized a variety of technologies for cancer immunotherapy. In particular, we have established a first class cGMP manufacturing process and SOPs for ex vivo activation and expansion of autologous immune cells.  All of our products are extensively validated for their safety and efficacy and have been used on cancer patients with positive results. Currently, we are offering the following cancer immunotherapy products.


CIK cell therapy

    Cytokine-induced killer (CIK) cells are a new type of immune cells.  CIK cells proliferate rapidly in vitro, maintain certain immune properties, and show cytotoxic effect on cancer cells. Since CIK cells express both CD3 and CD56 protein molecules, it is also known as NK cell (natural killer cell) like T lymphocytes, which combine the anti-tumor activities of T lymphocytes and NK cells. CIK cells can specifically recognize and kill cancer cells, but not harm normal cells. Numerous clinical trials have demonstrated that CIK cell therapy is highly beneficial for patients after radiotherapy and chemotherapy treatment, helping to eliminate the residual tumor cells and to prevent the recurrence of cancer cell proliferation.

 

Features:

    1.  Clear residual cancer cells and small lesions after surgery, radiotherapy, and chemotherapy and prevent tumor recurrence and metastasis;

    2. Reduce chemotherapy side effects and improve the efficacy of radiotherapy and chemotherapy;

    3. Can be used for patients who do not response well to radiotherapy and chemotherapy or show chemotherapeutic drug resistant;

    4. Relieve symptoms and prolong survival for patients with advanced cancer.

 

DC-CIK cell therapy 

    Dendritic cell activated -cytokine induced killer cells (DC-CIK) have being used to treat malignant melanoma, prostate cancer, kidney cancer, bladder cancer, ovarian cancer, colon cancer, colorectal cancer, breast cancer, cervical cancer, lung cancer, laryngeal cancer, nasopharyngeal cancer, pancreatic cancer, liver cancer, gastric cancer, leukemia and other blood cancer and multiple myeloma. For DC-CIK therapy, human peripheral blood mononuclear cells were in vitro induced into DC cells and CIK cells, respectively. DC cells are then matured under culture condition and co-cultured with CIK cells to obtain a mixed cell population. DC cells secrete high levels of IL -2, IL-12 that induce Th1 type cellular immune response in favor of eliminating tumor cells. Cytotoxicity of DC-CIK activity was significantly enhanced compared to CIK only.

                                                

Features:

    1. Attack and kill tumor cells specifically and do not harm normal cells;

    2. Rebuild and improve immune function in patients and prevent tumor recurrence and metastasis;

    3. Trigger immune memory and thus provide lasting tumor cell-killing effect;

    4. Increase the body's anti-tumor immune response that helps to eliminate residual tumor cells.

 

NK cell therapy 

    Natural killer cell (NK cell) is a core component of the human innate immunity and the basis of tumor cell immunity. Besides their main role in anti-tumor, anti-viral infection, and immune regulation, NK cells also participate in the occurrence of hypersensitivity and autoimmune diseases in some cases. NK cells are usually dormant, but once activated, they can penetrate into most tissues to attack tumor cells and virus-infected cells. The killing activity of NK cells does not restricted by MHC and does not rely on antibodies.

 

Features:

    1. Conduct non-specific killing of abnormal cells such as tumor cells, virus-infected cells, and mutated cells;

    2. Do not require antigen or mitogen sensitization for cytotoxic activity;

    3. Kill abnormal cells at early stage and act fast – not restricted by MHC molecules;

    4. Can be used for allogeneic transplant.

                                           

 

CAR-T cell therapy

    Chimeric antigen receptor T cell (CAR-T cell) therapy is an emerging and fast growing area of anti-cancer research.  CAR-T technology collects T cells from the patient, genetically inserts CAR into patient T cells, expands CAR-T cells ex vivo, and then infuses the modified CAR-T cells back into the patient. Once those CAR-T cells enter into the patient, they will find the target cancer cells through antibody-antigen binding, then the CAR-T cells will be activated and rapidly propagated in vivo, like normal antiviral response. CAR-T technology overcomes the conventional tumor-specific TCR -MHC restricted tumor targeting and thus solves the tumor cell escape problems. CAR-T cell therapy has obtained very promising results for treatment of leukemia, lymphoma, melanoma, glioma and other malignant tumors.


Features:

    1. The platform is universally applicable to different types of tumors;

    2. Superior specificity for targeted tumor cells;

    3. Long term sustainable anti-tumor effect.


For availability and purchase information of all CIB neural cell products please contact:  service@cib.cc

Tel:0755-23072081


Copyright 2008-2013 of Shenzhen city and three biological technology Co., Ltd. all rights reserved. All Rights Reserved